01Identity
Which material?
The label, chain profile, source species or tissue, purification and concentration are identified.
Polynucleotides · PN/PDRN · Hair and Scalp
Polynucleotides · PN/PDRN · Hair and Scalp
Poly
PN and PDRN are often grouped together, but the labels do not automatically describe the same product. Chain-length profile, molecular distribution, biological source, purification, concentration, excipients and intended use must be checked from the original dossier.
Laboratory or wound-healing mechanisms do not establish scalp effectiveness. Hair and skin uses, product forms and authorisation contexts remain separate.
Quick Orientation
Four questions before PN or PDRN
The product dossier comes before the class name.
A medically useful discussion joins nomenclature, source, composition, legal status, route and the matching human evidence.
02Composition
Which formulation?
Excipients, combinations, presentation, sterility and storage can change the product and its risks.
03Status
Which authorised use?
Country, product, route, indication and any off-label consideration are stated separately.
04Evidence
Which endpoint?
A scalp diagnosis and a measurable hair endpoint are distinguished from skin-quality aims.
PN and PDRN
DNA-derived polymers or fragments · product-dependent
Two related labels do not create one standard preparation.
Both terms are used for purified DNA-derived material, but naming conventions and molecular profiles vary. The actual product information remains decisive.
What can be described
- Identify a cell-free product by name, source, chain profile and formulation
- Evaluate one product for one defined scalp or skin question
- Document batch, route, tolerability and the agreed endpoint
- Position the product as an optional adjunct rather than a default treatment
What cannot be assumed
- Treat PN and PDRN as automatic synonyms
- Transfer evidence between unlike products, regions or routes
- Infer authorisation from a class name or imported packaging
- Promise regeneration, new follicles, density or permanent growth
Source, composition, product authorisation and intended route must be confirmed for the exact preparation; a class label cannot replace that review.
Medical Suitability
Diagnosis and product identity together
Five decisions determine whether discussion should continue.
Remote photographs may help frame the concern, but diagnosis, tissue examination, allergy risk, product status and an injection plan require personal assessment.
- 01
Define the hair question
Pattern, sudden, inflammatory, scarring and other forms of loss require different priorities.
- 02
Examine the scalp
Barrier, infection, inflammation, scarring and the proposed target plane are reviewed.
- 03
Identify the product
PN or PDRN name, source, chain profile, purification, excipients, batch and storage are confirmed.
- 04
Review individual risk
Allergy history, medicines, immune factors, pregnancy, healing and injection risks are considered.
- 05
Set an alternative and endpoint
Established therapy, observation, no treatment and a measurable stop rule stay visible.
Product and Application
Source · formulation · route
Each preparation keeps its own identity from vial to follow-up.
Raw material, purification, molecular distribution, excipients, sterile presentation and intended route are recorded together.
01Material
Confirm source and chain profile
The manufacturer dossier should define the DNA-derived material rather than rely on a broad market term.
- Name PN or PDRN as supplied
- Record source and purification
- Review molecular and concentration data
02Formulation
Check the complete preparation
Excipients, combination ingredients, sterility, batch and storage affect suitability and comparability.
- List active and supporting components
- Confirm sterile presentation and traceability
- Check country- and product-specific status
03Application
Link route to one target
Only after diagnosis and product review can a clinician consider a specific region and route.
- Separate scalp and skin aims
- Record route and treated region
- Define safety and outcome review points
A manufacturer protocol is not a personal treatment plan, and one product's instructions or study schedule cannot be applied to another preparation.
Evidence and Limits
Product-specific studies · limited scalp data
Early signals do not establish a PN/PDRN class effect.
Human scalp studies are small and use particular preparations and schedules. Product heterogeneity, limited controls and short follow-up restrict wider conclusions.
Keep the exact product
A finding belongs to the studied formulation, route, population and endpoint.
Separate PN and PDRN
Evidence for one label or molecular profile is not automatic evidence for the other.
Separate hair and skin
Skin texture or healing observations do not establish density or shaft change.
Keep alternatives visible
A research signal does not replace authorised medicines, diagnosis-led care or observation.
Current evidence cannot support a guaranteed response, a universal session schedule, superiority or long-term maintenance claim.
Individual Plan
One product · one target · one review
A plan is not built from the initials alone.
The diagnosis, exact preparation, status, route, alternatives and measurable endpoint determine whether a limited trial is defensible.
Record the baseline
Diagnosis, photographs, objective measure, medicines and previous care are documented.
Lock the identity
Product name, PN/PDRN label, source, formulation, batch, status and storage stay traceable.
Define the decision
One target and follow-up point are agreed without promising a response or fixed series.
Reassess before repeating
Tolerability, objective change, burden and alternatives determine the next step.
Course and Follow-Up
Injection response · clinical endpoint
An early local reaction is not a hair result.
Procedure-related changes are reviewed first; any hair endpoint requires a longer, standardised observation window.
- 01Early
Immediately
Redness, tenderness, swelling, small bumps, bruising or bleeding may reflect the injection procedure.
- 02Safety
During healing
Persistent inflammation, infection, allergy or nodules require product- and route-specific review.
- 03Outcome
At the endpoint
Comparable photographs and the agreed hair measure are assessed under consistent conditions.
- 04Decision
Before another step
The product, tolerability and objective findings are reconsidered rather than repeated automatically.
Risks and Alternatives
Source and formulation remain clinically relevant
A cell-free DNA-derived product can still cause harm.
Injection risks, allergy to source material or excipients, contamination, inflammation and uncertainty about product composition are addressed explicitly.
01Route
Procedure
Pain, bleeding, bruising, swelling, infection, inflammation and injection-related injury are possible.
02Material
Product
Source allergy, impurities, excipients, immune reaction or a storage problem may alter risk.
03Choice
Alternative
Authorised medication, observation, another clinical method, transplantation planning or no treatment may fit better.
04Decision
Withhold or stop
Treatment is withheld or stopped when the indication, consent, safety controls or follow-up cannot support a proportionate plan.
The exact product and batch must remain available for review if an unexpected reaction occurs; class-level reassurance is insufficient.
Istanbul and Follow-Up
Product availability and continuity
International care requires more than access to one vial.
The product dossier, local status, in-person examination and a workable follow-up route are considered before any intervention.
01Before travel
Prepare the record
History, medicines, allergies, previous care and comparable images organise the consultation.
02In Istanbul
Confirm the preparation
Diagnosis, source, composition, status, route, risks and alternatives are reviewed in person.
03Treatment day
Retain traceability
Any use would document the original product, batch, region, route and immediate response.
04After return
Plan later review
Aftercare, contact pathway and the objective endpoint are agreed before the return journey.
The Doctor Aslan Approach
Product before promise
PN and PDRN are compared, not collapsed into one treatment.
The exact material, formulation, authorisation context and target tissue remain visible. A laboratory mechanism is not presented as proof of regeneration or growth.
Name the product
PN/PDRN terminology is checked against the original documentation.
Trace source and formulation
Raw material, purification, excipients, batch and storage are reviewed.
Separate clinical targets
Scalp and skin evidence are not exchanged.
Review rather than package
A further step needs a fresh safety and endpoint decision.
Medical responsibility: Dr İsmail AslanMedical review: 24 August 2026General patient information about polynucleotide, PN and PDRN preparations; no personal diagnosis, protocol or outcome guarantee
Frequently Asked Questions
Short and clear
Questions commonly asked before a decision.
These answers provide general orientation and do not replace personal diagnosis or treatment planning.
01What is Polynucleotides (PN/PDRN)?+
Polynucleotides (PN/PDRN) is described on this page as one defined clinical route. Its role, limits and possible alternatives are considered together rather than treating the method name as a personal recommendation.
02Who may be assessed for Polynucleotides (PN/PDRN)?+
Suitability depends on the medical question, history, examination, the exact product or device where relevant, realistic aims and an individual benefit–risk assessment.
03What remains undecided after an online review?+
Diagnosis, definitive suitability, the treatment protocol, product, dose or device settings, expected response and the option not to proceed remain subject to personal medical assessment.
04How are treatment and follow-up in Istanbul planned?+
The in-person examination remains the decision point. Expected early reactions, warning signs, the direct contact route, return travel and access to appropriate local medical care are discussed before treatment.
Next Step
Identify the preparation · define the target